Following the press release of December 10th 2007, where Lavipharm announced the approval to market its fentanyl patch in Germany in anticipation that the launch would take place within the second half of 2008, the Company announces that the product has just been launched, making Germany the second European market after Greece. The fentanyl patch, produced at Lavipharm?s manufacturing facilities in Peania, Attica, is sold in Germany by Mylan Dura, former Merck Dura GmbH, under the brand name Fentanyl Dura. National and pan European approvals in other markets are pending.
"The fentanyl patch, developed by our research laboratories in the USA, is the second transdermal drug delivery system that we bring to the international market, next to our nitroglycerin patch", said Dr. Athanase Lavidas, Chairman & CEO of Lavipharm. "The launch by our marketing partner in Germany Mylan Dura, a company with a strong presence in the German market, is an important milestone for Lavipharm, as we diligently continue to progress with the registrations and new partnerships in other markets across the globe. The gradual roll out of this important product represents yet another example of Lavipharm's commitment to innovation and to establishing a competitive edge in the field of pharmaceutical technology".
Lavipharm is an integrated Group of companies engaged in the research, development, production, import, marketing, sales and provision of logistics services of pharmaceutical, dermocosmetic and healthcare products in Greece with a strong international presence.